HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jørgensen, J. O. Articles by Richelsen, B. Search for Related Content PubMed Articles by Jørgensen, J. O. Articles by Richelsen, B.

Serum concentrations of insulin-like growth factors (IGFs), IGF binding proteins 1 and 3 and growth hormone binding protein in obese women and the effects of growth hormone administration: a double-blind, placebo-controlled study

Jørgensen JOL, Pedersen SB, Borglum J, Frystyk J, Ho KKY, Christiansen JS, Ørskov H, Blum WF, Richelsen B. Serum concentrations of insulin-like growth factors (IGFs), IGF binding proteins 1 and 3 and growth hormone binding protein in obese women and the effects of growth hormone administration: a double-blind, placebo-controlled study. Eur J Endocrinol 1995;133:65–70. ISSN 0804–4643

Obesity is associated with suppressed growth hormone (GH) concentrations but relatively little is known about insulin-like growth factors(IGFs) and binding proteins for GH and IGFs (GHBP and IGFBPs) and the modulatory effect of GH administration. In a double-blind, crossover design we studied the impact of 5 weeks of placebo or GH administration (0.03 mg·kg^–1 body wt·day^–1) in nine obese women (mean± SEM; age 30.4 ± 2.4 years; body mass index 37.0 ± 2.8kg/m²) on IGF-I, IGF-II, IGFBP-1 and -3 and GHBP. Serum IGF-I (µg/l) levels were subnormal and increased significantly following GH (117 ± 16 (placebo) vs 434 ± 33 (GH) vs 198 ± 15 (control (p < 0.01)). By contrast, serum IGF-II (µg/l) levels were in the normal range and remained unchanged (608 ± 20 (placebo) vs 647 ± 40 (GH) (NS)). Serum IGFBP-3 was in the normal range and increased significantly during GH treatment, although relatively less than IGF-I, such that the molar ratio between IGF-I and IGFBP-3 increased with GH treatment, whereas the ratio between IGF-I + IGF-II and IGFBP-3 remained unchanged. Serum IGFBP-1 was low in the placebo situation but became further and almost completely suppressed during GH treatment. During a 2-h hyperinsulinemic, euglycemic glucose clamp, IGFBP-1 decreased in the placebo study and remained suppressed during GH. Serum GHBP (nmol/l) levels were elevated substantially compared to non-obese controls (p < 0.001) and did not change during GH treatment (2.37 ± 0.36 (placebo) vs 2.21 ± 0.25 (GH) vs 0.80 ± 0.19 (control)). In conclusion. obese subjects have low total IGF-I levels but may exhibit relatively increased free IGF-I levels due to the suppression of IGFBP-1. This presumed elevation in free IGF-1 in obesity may explain the normal levels of IGFBP-3 and IGF-II, which contrasts with classic GH deficiency. Furthermore, obese subjects are responsive to exogenous GH in terms of total IGF-I generation and normalization of the ratio between IGF-I and IGFBP-3. Finally, obesity is associated with marked elevations in GHBP levels that were unaffected by 5 weeks of GH administration.

Jens OL Jørgensen, Medical Department M, Aarhus Kommunehospital, DK-8000 C, Aarhus, Denmark

This article has been cited by other articles:

				A. Eliakim, J. A. Brasel, S. Mohan, W. L. T. Wong, and D. M. Cooper Increased physical activity and the growth hormone-IGF-I axis in adolescent males Am J Physiol Regulatory Integrative Comp Physiol, July 1, 1998; 275(1): R308 - R314. [Abstract] [Full Text] [PDF]

				M. A. Llopis, M. L. Granada, G. Cuatrecasas, X. Formiguera, L. Sánchez-Planell, A. SanmartÍ, A. Alastrué, M. Rull, A. Corominas, and M. Foz Growth Hormone-Binding Protein Directly Depends on Serum Leptin Levels in Adults with Different Nutritional Status J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2006 - 2011. [Abstract] [Full Text]

				C. H. Gravholt, R. W. Naeraa, S. Fisker, and J. S. Christiansen Body Composition and Physical Fitness Are Major Determinants of the Growth Hormone-Insulin-Like Growth Factor Axis Aberrations in Adult Turner's Syndrome, with Important Modulations by Treatment with 17{beta}-Estradiol J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2570 - 2577. [Abstract] [Full Text] [PDF]

				C. A. M. Roelen, H. P. F. Koppeschaar, W. R. de Vries, Y. E. M. Snel, M. E. Doerga, P. M. J. Zelissen, J. H. H. Thijssen, and M. A. Blankenstein Visceral Adipose Tissue Is Associated with Circulating High Affinity Growth Hormone-Binding Protein J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 760 - 764. [Abstract] [Full Text] [PDF]

				S. Fisker, N. Vahl, J. O. L. Jorgensen, J. S. Christiansen, and H. Orskov Abdominal Fat Determines Growth Hormone-Binding Protein Levels in Healthy Nonobese Adults J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 123 - 128. [Abstract] [Full Text] [PDF]